To determine whether NR2F1 is sufficient to enhance drug tolerance, we induced the expression of NR2F1 in BRAF-V600E 1205Lu, WM793, and A375 melanoma cell lines and treated them with or without BRAFi + MEKi (Figure 2A). Here, BRAF is linked to melanoma.